Your SlideShare is downloading. ×
0
Combio - Terveydenhuollon biomateriaalit
Combio - Terveydenhuollon biomateriaalit
Combio - Terveydenhuollon biomateriaalit
Combio - Terveydenhuollon biomateriaalit
Combio - Terveydenhuollon biomateriaalit
Combio - Terveydenhuollon biomateriaalit
Combio - Terveydenhuollon biomateriaalit
Combio - Terveydenhuollon biomateriaalit
Combio - Terveydenhuollon biomateriaalit
Combio - Terveydenhuollon biomateriaalit
Combio - Terveydenhuollon biomateriaalit
Combio - Terveydenhuollon biomateriaalit
Combio - Terveydenhuollon biomateriaalit
Combio - Terveydenhuollon biomateriaalit
Combio - Terveydenhuollon biomateriaalit
Combio - Terveydenhuollon biomateriaalit
Combio - Terveydenhuollon biomateriaalit
Combio - Terveydenhuollon biomateriaalit
Combio - Terveydenhuollon biomateriaalit
Combio - Terveydenhuollon biomateriaalit
Combio - Terveydenhuollon biomateriaalit
Combio - Terveydenhuollon biomateriaalit
Combio - Terveydenhuollon biomateriaalit
Combio - Terveydenhuollon biomateriaalit
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Combio - Terveydenhuollon biomateriaalit

562

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
562
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide
  • Tutkimusmenojen osuus bruttokansantuotteesta on kasvanut nopeasti yritysten tutkimuspanosten kasvun myötä. Sen sijaan julkinen tutkimus- ja teknologiarahoitus on ollut useita vuosia suunnilleen samalla tasolla. Perusosaamisen kehittämisen rahoitus on hitaasti kasvanut (Suomen Akatemia, yliopistot, valtion tutkimuslaitokset), sen sijaan teknologiarahoitus on jo neljä vuotta pysynyt samana. OECD:n tutkimusten mukaan tasapainoinen julkinen rahoitus julkiseen tutkimukseen ja yritysten tutkimus- ja kehitystyöhön nopeuttaa tulosten hyödyntämistä. Julkisella teknologiarahoituksella vauhditetaan innovaatioiden syntyä ja teknologian hyödyntämistä laajasti sekä myös huolehditaan osaamisen uudistumisesta; rahoituksella edistetään yhteistyötä ja verkottumista niin yritysten välillä kuin yliopistojen ja tutkimuslaitosten kanssa sekä huolehditaan kansainvälisestä teknologian siirrosta.
  • Transcript

    • 1. Tekes – Focusing on Biomaterial Technology Ms. Aila Maijanen Tekes, National Technology Agency of Finland Senior Technology Advisor
    • 2. Tekes Focusing on biomaterial technology Human Spare Parts Oct 21, 2004 - Brussels Aila Maijanen National Technology Agency Tekes Senior technology advisor
    • 3. Content: <ul><li>National Technology Agency Tekes: Mission and Activities </li></ul><ul><li>Tekes Technology Programmes </li></ul><ul><li>Combio – Commercialisation of Biomaterials Technology Programme </li></ul><ul><li>Conclusion </li></ul>
    • 4. Public sector activities of R&amp;D in Finland Ministry of Trade and Industry DM 32190 04-2003 Copyright © Tekes Academy of Finland Universities Ministry of Trade and Industry Sitra Finnvera Oyj Finpro PARLIAMENT GOVERNMENT VTT Tekes Science and Technology Policy Council Regional TE-Centres Other ministries and their institutes Ministry of Education
    • 5. Tekes’ mission statement <ul><li>Tekes’ primary objective is to promote the competitiveness of Finnish industry and the service sector by technological means. </li></ul><ul><li>Activities aim to diversify production structures, increase production and exports, and create a foundation for employment and societal well-being. </li></ul>DM 32189 04-2003 Copyright © Tekes
    • 6. Tekes core activities Selective project funding Technology programmes DM 32189 11-2003 Copyright © Tekes Development of the innovation environment Activation for innovation Regional technological cooperation and promotion of regional success International technological cooperation and international expansion of companies
    • 7. Tekes technology funding in the state budget 349 386 316 252 244 386 395 415 390 379 Million euros DM 26047 11-2003 Copyright © Tekes During the years 2000-2004 Tekes also had an annual allocation of 5-10 million euros from the EU Structural Funds as the EU share. The funding resources for industrial R&amp;D loans and capital loans for R&amp;D merged in 2004. National share of EU Structural Funds Industrial R&amp;D loans Capital loans for R&amp;D Industrial R&amp;D grants Coordination of programmes Research funding
    • 8. Tekes Overseas Offices DM 26047 04-2004 Copyright © Tekes Helsinki Brussels San Jose Washington, D.C. Tokyo Beijing
    • 9. Technology Units at the TE-Centres DM 26047 04-2004 Copyright © Tekes Technology units at the Employment and Economic Development Centres (TE-Centres) offer Tekes&apos; services to companies and research units. Lapland Oulu Kajaani Seinäjoki Kuopio Jyväskylä Joensuu Mikkeli Tampere Pori Lappeenranta Turku Tekes, Helsinki Vaasa Lahti
    • 10. Total Tekes R&amp;D funding in 2003 by field of technology Information and communications technology 115 million euros Other funding 4 million euros Space activities 18 million euros Bio- and chemical technology 107 million euros Product and production technology 74 million euros Energy, environment and construction technologies 74 million euros DM 80983 01-2004 Copyright © Tekes Total 392 million euros and 2,196 projects
    • 11. Tekes research funding in 2003 Total funding 162 million euros and 801 projects VTT 36 million euros Participation fees for ESA programmes, 13 million euros Other research funding 8 million euros Universities 102 million euros Other research institutes 3 million euros In many research projects there are participants from several universities or research institutes. DM 80983 01-2004 Copyright © Tekes
    • 12. Technology programme model Tekes Grants Company R&amp;D projects Research projects of research institutes and universities Synergy Networking Part financing <ul><li>preparation </li></ul><ul><li>coordination </li></ul><ul><li>decision making </li></ul>DM 30256 02-2004 Copyright © Tekes Grants Loans Capital loans Pictures: © ESA, Okmetic, Stora Enso <ul><li>Steering group </li></ul><ul><li>enterprises </li></ul>
    • 13. Bio- and Chemical Technology Picture: © Elcotec DM 30256 02-2004 Copyright © Tekes Technology programmes in 2004 2000-2004 2001-2004 2001-2004 2001-2006 2003-2006 2003-2007 20 42 87 110 21 26 18 33 10 11 2 23 27 56 50 34 5 18 Process Integration * Innovation in Foods NeoBio - Novel Biotechnology * Drug 2000 ** Wood Material Science COMBIO - Commercialisation of Biomaterials = Intertechnological programme = In cooperation with the Academy of Finland * ** Total budget mill. euros Participating research units compa- nies
    • 14. COMBIO - Commercialisation of Biomaterials DM 65640 09-2003 Copyright © Tekes The goal of the COMBIO programme is to further develop the strong Finnish biomaterial technology base in health care and to use business technologies to support the commercialisation of research results <ul><li>Time span: 2003-2007 </li></ul><ul><li>Extent: Approximately 26 million euros </li></ul><ul><li>Responsibility: Mika Sievi-Korte, Tekes Aila Maijanen, Tekes </li></ul><ul><li>Programme Manager: Heikki Laurila, </li></ul><ul><li> Frux Advisors Ltd. </li></ul><ul><li>Further information: www.tekes.fi/ohjelmat/combio </li></ul>
    • 15. How to enhance commercialisation of medical biomaterials research ? <ul><li>focusing on market-driven opportunities </li></ul><ul><li>training of business skills, IPR and regulatory issues </li></ul><ul><li>long-term funding of research and R&amp;D in key technologies </li></ul><ul><li>increasing the critical mass of research projects </li></ul><ul><li>promoting collaboration within Finland </li></ul><ul><li>promoting the biomaterials field for vc’s </li></ul><ul><li>promoting the internationalisation of Finnish biomaterials companies </li></ul>
    • 16. Background <ul><li>The ageing population is the single most important reason for the rapid growth of the biomaterials sector in health care </li></ul><ul><ul><li>The number of persons over 60 years is growing at a rate of 1.5 percent annually </li></ul></ul><ul><ul><li>the human body is “designed” to hold out for 30-40 years </li></ul></ul><ul><ul><li>many tissues start to deteriorate at an increasing speed after the age of 30 </li></ul></ul><ul><ul><li>tissues can be repaired using biomaterials and by combining tissue engineering and stem cell technology with biomaterials </li></ul></ul><ul><li>Other sources of growth are new technologies in administering drugs and the evolutionary development of several surgical products that are implementing the use of biomaterials </li></ul>DM 65640 09-2003 Copyright © Tekes
    • 17. Structure and Development <ul><li>Globally, there are about 7,500 companies in the sector </li></ul><ul><li>Turnover is about 50 billion euros </li></ul><ul><ul><li>an average of 6.5 million euros/company </li></ul></ul><ul><li>The growth of different market segments varies between 8 and 40 percent annually </li></ul><ul><ul><li>the average market growth of the pharmaceutical industry is 8 percent annually </li></ul></ul><ul><li>Growth in the first half of 2003 was even more rapid than expected </li></ul><ul><ul><li>there have been extensive mergers and acquisitions in 2003 because companies are seeking new technologies and distribution channels (M&amp;A has not done away with overcapacity) </li></ul></ul>DM 65640 09-2003 Copyright © Tekes
    • 18. Vision <ul><li>3-5 globally-acting companies in Finland in 2010 </li></ul><ul><li>Turnover 500 million euros (or even more) </li></ul><ul><ul><li>the turnover from subcontractors has to be added to the above </li></ul></ul><ul><li>80 percent of existing companies will disappear due to mergers and closures </li></ul><ul><ul><li>even in the case of a closure, know-how will remain in Finland and is transferable to other companies </li></ul></ul><ul><li>New companies with similar courses of development will constantly appear (80 percent will disappear) </li></ul>DM 65640 09-2003 Copyright © Tekes
    • 19. Focus Areas <ul><li>Materials and methods in tissue engineering </li></ul><ul><li>New materials for drug delivery </li></ul><ul><li>Implants MAIN FOCUS: COMMERCIALISATION! </li></ul>The programme focuses on three technology areas DM 65640 09-2003 Copyright © Tekes
    • 20. Programme structure: Material technology Biomechanical modelling Cell biology Stem cell research New materials for drug delivery Multifunctional implants Tissue engineering: bone soft tissue cartilage Company R&amp;D Projects Company R&amp;D Projects Company R&amp;D projects Company R&amp;D projects
    • 21. Themes for Public Projects <ul><li>Biological materials and composites for artificial tissues </li></ul><ul><li>Bone tissue engineering from stem cells and scaffolds </li></ul><ul><li>Implants for tissue engineering </li></ul><ul><li>Release of drugs, structural studies and modelling </li></ul><ul><li>Biomaterials in ophthalmic surgery </li></ul><ul><li>Photopolymerisable gels </li></ul><ul><li>Implants based on memory metals </li></ul><ul><li>Multifunctional biomaterials </li></ul><ul><li>Biomechanically optimised multicomponent implants </li></ul><ul><li>Antimicrobial properties of bioactive glass and Si gel </li></ul><ul><li>Porous biodegradable or bioactive material </li></ul><ul><li>Optical fibre composite for medicine and dentistry </li></ul><ul><li>Bioactive resorbable composite for bone repair </li></ul>DM 65640 09-2003 Copyright © Tekes
    • 22. State of the Programme <ul><li>Participating research units 23 </li></ul><ul><li>Participating companies 24 </li></ul><ul><li>Projects underway 20 </li></ul><ul><ul><li>research projects 13 </li></ul></ul><ul><ul><li>company projects 7 </li></ul></ul>DM 65640 09-2003 Copyright © Tekes
    • 23. Conclusion: <ul><li>Finland provides an excellent infrastructure for research and R&amp;D on biomaterials and tissue engineering due to advanced </li></ul><ul><ul><li>educational system </li></ul></ul><ul><ul><li>public health care </li></ul></ul><ul><ul><li>innovation and technology policy </li></ul></ul><ul><li>proven process including </li></ul><ul><ul><li>basic reseach </li></ul></ul><ul><ul><li>preclinical and clinical research </li></ul></ul><ul><ul><li>product development </li></ul></ul><ul><ul><li>process development </li></ul></ul><ul><ul><li>full-scale manufacturing </li></ul></ul><ul><li>Products taken from lab to market! </li></ul>
    • 24. Thank You!

    ×